Skip to main content
Explore URMC

menu

A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic Amyloid Light-chain (AL) Amyloidosis

Research Question:
Do the drugs daratumumab, cyclosphosphamide, bortezomib and dexamethasone help patients with amyloidosis?

Basic Study Information

Purpose:
The purpose of this study is to evaluate the efficacy and safety of daratumumab plus cyclophosphamide, bortezomib and dexamethasone (CyBorD) compared with CyBorD alone in treatment of newly diagnosed amyloid light chain (AL) amyloidosis participants.

Location: University of Rochester Medical Center

Study Contact Information

Study Coordinator: Study Contact
Phone: (844) 434-4210
Email: JNJ.CT@sylogent.com

Additional Study Details

Contact This Study

This field is required
This field is required
You must agree to be contacted to continue.

Return to Search